F8 and hemophilia A: In hemophilia A patients, which have reduced or diminished endogenous FVIII levels in the circulation, replacement therapy with recombinant or plasma-derived FVIII can lead to the formation of FVIII-neutralizing antibodies, commonly referred to as “inhibitors”.